Literature DB >> 18405968

Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells.

Eugenia Flores-Figueroa1, Juan José Montesinos, Patricia Flores-Guzmán, Guillermo Gutiérrez-Espíndola, Rosa María Arana-Trejo, Sebastián Castillo-Medina, Adrián Pérez-Cabrera, Erika Hernández-Estévez, Lourdes Arriaga, Hector Mayani.   

Abstract

Two different reports, including one from our own group, have recently demonstrated the presence of severe chromosomal abnormalities in mesenchymal stem cells (MSC) from patients with myelodysplastic syndromes (MDS). In the present study, we have assessed whether such cytogenetic abnormalities result in functional deficiencies in vitro. We found that both normal and MDS MSC showed similar expression patterns of cell adhesion molecules and extracellular matrix proteins. MDS MSC layers showed the capability to differentiate towards adipocytes, chondrocytes and osteoblasts, and supported the growth of early umbilical cord blood progenitors in a co-culture system. Unstimulated MDS MSC secreted more IL-1beta and after treatment with TNFalpha, they secreted more SCF, as compared to their normal counterparts. The present study demonstrates that, in spite of harboring severe chromosomal alterations, most of the functional properties of MDS-derived MSC remain normal, including their ability to support normal hematopoiesis in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405968     DOI: 10.1016/j.leukres.2008.02.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  36 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

3.  Casting doubt on the safety of "off-the-shelf" mesenchymal stem cells for cell therapy.

Authors:  Pranela Rameshwar
Journal:  Mol Ther       Date:  2009-02       Impact factor: 11.454

4.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 5.  Concise review: ex vivo expansion of cord blood-derived hematopoietic stem and progenitor cells: basic principles, experimental approaches, and impact in regenerative medicine.

Authors:  Patricia Flores-Guzmán; Verónica Fernández-Sánchez; Hector Mayani
Journal:  Stem Cells Transl Med       Date:  2013-10-07       Impact factor: 6.940

Review 6.  Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.

Authors:  Jingya Wang; Zhijian Xiao
Journal:  Stem Cell Investig       Date:  2014-08-21

7.  In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity.

Authors:  Juan J Montesinos; María de L Mora-García; Héctor Mayani; Eugenia Flores-Figueroa; Rosario García-Rocha; Guadalupe R Fajardo-Orduña; Marta E Castro-Manrreza; Benny Weiss-Steider; Alberto Monroy-García
Journal:  Stem Cells Dev       Date:  2013-06-14       Impact factor: 3.272

Review 8.  Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation.

Authors:  Charalampos Pontikoglou; Frédéric Deschaseaux; Luc Sensebé; Helen A Papadaki
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

9.  Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.

Authors:  Youshan Zhao; Dong Wu; Chengming Fei; Juan Guo; Shuncheng Gu; Yang Zhu; Feng Xu; Zheng Zhang; Lingyun Wu; Xiao Li; Chunkang Chang
Journal:  Haematologica       Date:  2014-10-31       Impact factor: 9.941

Review 10.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.